Incannex Healthcare Inc (IXHL)
2.50
-0.28
(-10.07%)
USD |
NASDAQ |
May 17, 16:00
2.52
+0.02
(+0.80%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 40.48M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 46.22% |
| Valuation | |
| PE Ratio | 2.382 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.807 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. |
| URL | https://www.incannex.com.au |
| Investor Relations URL | https://www.incannex.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 22, 2024 (est.) |
| Last Earnings Release | Feb. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. |
| URL | https://www.incannex.com.au |
| Investor Relations URL | https://www.incannex.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 22, 2024 (est.) |
| Last Earnings Release | Feb. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |